

A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2

Authors: Hebang Yao^{1,2,#}, Hongmin Cai^{1,2,#}, Tingting Li^{1,2,#}, Bingjie Zhou^{2,3,#},

5 Wenming Qin⁴, Dimitri Lavillette^{3,*}, Dianfan Li^{1,*}

Affiliation: ¹State Key Laboratory of Molecular Biology, State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), 320 Yueyang Road, Shanghai 200030, China.

10 ²University of CAS, Beijing 101408, China.

³CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai CAS, 320 Yueyang Road, Shanghai 200031, China.

⁴National Facility for Protein Science in Shanghai, Shanghai Advanced Research

15 Institute (Zhangjiang Laboratory), CAS, Shanghai, 201210, China.

#Equal contribution.

*Correspondence: dianfan.li@sibcb.ac.cn; dlaville@ips.ac.cn

20

ABSTRACT

A key step to the SARS-CoV-2 infection is the attachment of its Spike receptor-binding domain (S RBD) to the host receptor ACE2. Considerable research have been devoted to the development of neutralizing antibodies, including llama-derived single-chain nanobodies, to target the receptor-binding motif (RBM) and to block ACE2-RBD binding. Simple and effective strategies to increase potency are desirable for such studies when antibodies are only modestly effective. Here, we identify and characterize a high-affinity synthetic nanobody (sybody, SR31) as a fusion partner to improve the potency of RBM-antibodies. Crystallographic studies reveal that SR31 binds to RBD at a conserved and ‘greasy’ site distal to RBM. Although SR31 distorts RBD at the interface, it does not perturb the RBM conformation, hence displaying no neutralizing activities itself. However, fusing SR31 to two modestly neutralizing sybodies dramatically increases their affinity for RBD and neutralization activity against SARS-CoV-2 pseudovirus. Our work presents a tool protein and an efficient strategy to improve nanobody potency.

Introduction

40 SARS-CoV-2, the pathogenic virus for COVID-19, has caused a global pandemic since its first report in early December 2019 in Wuhan China (1), posing a gravely crisis for health and economic and social order. SARS-CoV-2 is heavily decorated by its surface Spike (S) (2, 3), a single-pass membrane protein that is key for the host-virus interactions. During the infection, S is cleaved by host proteases (4, 5), yielding the N-terminal S1 and the C-terminal S2 subunit. S1 binds to angiotensin-converting enzyme 2 (ACE2) (6-10) on the host cell membrane via its receptor-binding domain (RBD), causing conformational changes that trigger a secondary cleavage needed for the S2-mediated membrane fusion at the plasma membrane or in the endosome. Because of this essential role, RBD has been a hot spot for the development of therapeutic 45 monoclonal antibodies (mAbs) and vaccine (11-28).

50

55 Llama-derived heavy chain-only antibodies (nanobodies) are attractive bio-therapeutics (29). These small (~14 kDa) proteins are robust, straightforward to produce, and amenable to engineering such as mutation and fusion. Owing to their ultra-stability, nanobodies have been reported to survive nebulization, a feature that has been explored for the development of inhaled nanobodies to treat respiratory viral diseases (30, 31) which categorizes COVID-19. Owing to their high sequence similarities with human type 3 VH domains (VH3), nanobodies are known to cause little immunogenicity (29). For the same reason, they can be humanized with relative ease to reduce 60 immunogenicity when needed. Therefore, nanobodies as biotherapeutics are being increasingly recognized. Examples of nanobody drugs include caplacizumab (32) for the treatment of acquired thrombotic thrombocytopenic purpura, and ozoralizumab and vobarilizumab that are in the clinical trials for rheumatoid arthritis (29, 33). Recently, several groups have independently reported neutralizing nanobodies (22, 34-39) or 65 single-chain VH antibodies (40) against SARS-CoV-2 with variable potencies.

70 We have recently reported several synthetic nanobodies (sybodies) which bind RBD with various affinity and neutralizing activity (35). Affinity and neutralizing activity are very important characteristics for therapeutic antibodies, and they can be improved by a number of ways such as random mutagenesis (22, 36) and structure-based design. Previously, in the case of one modestly-neutralizing sybody MR17, we have determined its structure and designed a single mutant that improves its potency by over 23 folds (35). The rational design approach, while very effective, inevitably requires high-resolution structural information which are non-trivial to obtain. 75 Generally applicable tools will be welcome.


Here, we report a strategy to increase sybody potency by biparatopic fusion with SR31, a sybody that binds RBD tightly with a K_D of 5.6 nM. As revealed by crystal structure, SR31 engages the RBD at a conserved site that is distal to the RBM. As such, it does not neutralize SARS-CoV-2 but forms non-competing pairs with several other RBM-binders and increases their neutralization potency when conjugated. SR31 may be used as a general affinity-enhancer for both detection and therapeutic applications.

Results and Discussion

85 A high-affinity RBD binder without neutralizing activity

Previously, we generated 99 sybodies from three highly diverse synthetic libraries by ribosome and phage display with *in vitro* selections against the SARS-CoV-2 RBD. Most of the sybody binders showed neutralizing activity. Interestingly, about 10 sybodies bind RBD but showed no neutralizing activities (35) even at 1 μ M concentration.


90 One such sybodies, named SR31, was characterized in this study. In analytic fluorescence-detection size exclusion chromatography (FSEC), SR31 caused earlier retention of RBD (Fig. 1A) which was included at a low concentration (0.5 μ M), suggesting nanomolar affinity for SR31-RBD binding. This was confirmed by bio-layer interferometry analysis (Fig. 1B) which showed a K_D of 5.6 nM and an off-rate of 1×10^{-3} s $^{-1}$. Consistent with its inability to neutralize SARS-CoV-2 pseudovirus, SR31 did not affect RBD-ACE2 binding (Fig. 1C).



100 **Fig. 1. Characterization of the SR31-RBD complex.** (A) FSEC of RBD in the absence (black) and presence (blue) of SR31. (B) Bio-layer interferometry (BLI) assay with RBD immobilized and SR31 as analyte at three concentrations (nM). (C) SR31 does not inhibit ACE2 binding. A RBD-coated sensor saturated with SR31 was soaked in 50 nM of SR31 with (blue) and without (black) 25 nM ACE2. As a control, the assay was performed with RBD immobilized and ACE2 as analyte (red). (D) Purification (SEC and SDS-PAGE) and crystallization of the RBD-SR31 complex.

Structure of SR31 in complex with RBD

To characterize the SR31-RBD interactions in detail, we purified the complex (Fig. 1D), and obtained crystals (Fig. 1D) that diffracted to 1.97 Å resolution (Table 1). The structure was solved by molecular replacement using the published RBD and sybody structures (PDB IDs 6M0J and 5M13) (6, 41) as search models. The structure was refined to $R_{\text{work}}/R_{\text{free}}$ of 0.182/0.207 (Table 1). The asymmetric unit contained one molecule each for the RBD and SR31, indicating an expected 1:1 stoichiometry.




115 **Fig. 2. Crystal structure of the SR31-RBD complex.** (A) The overall structure of SR31 (light blue) in complex with RBD (grey) which contains Asn343-linked glycans (cyan). The expanded view highlights a deep hydrophobic pocket for CDR3 binding. (B) The overall structure viewed at a different angle. (C) 2Fo-Fc map of the Asn343-linked glycans. MAN, mannose; BMA, β -D-mannose; FUC, fucose; NAG, N-acetylglucosamine. (D-G) Detailed interactions between RBD and the CDR1 (D), CDR2 (E), and CDR3 (F, G). The hydrophobic network formed between CDR3 (orange) and the hydrophobic pocket in RBD (grey) is shown in G. Residues from SR31 are labeled with black texts and residues from RBD are labeled with grey texts. Dash lines indicate hydrogen bonds or salt bridges within 3.6 Å.

SR31 binds to the RBD sideways at a buried surface area of 1,386.3 Å² (**Fig. 2A**), which is significantly larger than that for the previously reported sybodies SR4 (727.4 Å²) and MR17 (853.944 Å²) (35). The binding surface is near a heavily decorated 130 glycosylation site, Asn343 (**Fig. 2A-2C**), which, although at an apparent strategic position to possibly divide the accessible surfaces for immune surveillance, does not show clashes with SR31. All three CDRs participated in the interaction by providing five (CDR1), three (CDR2), and nine H-bonds (CDR3) (**Fig. 2E-2G**). Peculiarly, the 135 CDR3, which contains a cluster of hydrophobic side chains that include Met99, Val100, Phe102, Trp103, and Tyr104, inserted into a greasy pocket (**Fig. 2B**) in the RBD that was lined with twelve hydrophobic/aromatic residues (**Fig. 2F**). Unlike salt bridges, hydrophobic interactions are more tolerant to environment such as change of pH and ionic strength. In addition, they are less specific and thus less likely to be affected by mutations. This binding mode thus makes SR31 an attractive candidate for detection 140 purposes.

Most RBD-targeting neutralizing antibodies, including neutralizing nanobodies characterized so far (8, 13-15, 19, 20, 22-24, 26-28, 34, 35, 37), engage the RBD at the receptor-binding motif (RBM) (**Fig. 3A**), thus competing off ACE2 and preventing viral 145 entry. Aligning the ACE2 structure to the SR31-RBD structure showed that the SR31-binding epitope is distant from the RBM (**Fig. 3A**). Comparing the epitopes of existing monoclonal antibodies showed that the SR31 epitope partly overlaps with CR3022 (12) and the recently identified EY6A (22) (**Fig. 3B, 3C**). It has been established that the binding of the bulky CR3022 and EY6A at the interface between RBD and the N-terminal domain (NTD) of the adjacent monomer destabilizes the S trimer and converts 150 the pre-fusion conformation to the infection-incompetent post-fusion state, thus conferring neutralization activity (21, 22). Despite the epitope overlapping, SR31 approaches RBD at a different angle to that of CR3022 (**Fig. 3C**). This angular difference, together with its minute size, may allow SR31 to bind two of the three sites in the ‘open’-S (3): the ‘up-RBD’, and the ‘down-RBD’ at the clockwise monomer (**Fig. 3D**). Taken together, the structural data rationalize the high-affinity binding between SR31 and RBD, and its inability to neutralize SARS-CoV-2.

Because nanobodies are relatively easy to produce, the availability of nanobodies 160 that recognize a wide spectrum of epitopes can be a useful toolkit to probe binding mode of uncharacterized antibodies using competitive binding assays. They may also be used to select binders with new epitopes by including them as pre-formed sybody-RBD complexes during *in vitro* selection (and thus excluding binders at the same site).



165

Fig. 3. The SR31 epitope. (A) SR31 (blue) binds to RBD (grey) at a surface distal to the binding site of ACE2 (red). (B) Comparison of the SR31 epitope with epitopes for other RBD-targeting nanobodies (22, 35, 36, 39) and mAbs (13-15, 19, 20, 23, 24, 26-28). Red, the collective epitope of RBM-binders; blue, the SR31 epitope; magenta, the collective epitope of CR3022 and EY6A; orange, the overlap between the CR3022/EY6A and SR31 epitope. (C) SR31 (blue) binds RBD (grey) at a surface that overlaps with the epitope of CR3022 (orange and cyan) but approaches RBD at a different angle. (D) The binding site of SR31 in the context of the S trimer at its pre-fusion 'open' state with one RBD in the 'up' conformation and two in the 'down' conformation. The structure (PDB ID 6yvb) (3) is viewed from the 'top' (perpendicular to the viral membrane). The SR31 epitope is shown in blue. The three RBDs are colored green. SR31 (magenta cartoon) was aligned to the S trimer (surface presentation) by superposing the SR31-RBD structure to each of the RBD. '+', no or minor clashes; '−', with severe clashes.

170

175

180

SR31-RBD structure suggests high RBD domain stability

Structure alignment of SR31-RBD with ACE2-RBD revealed that the two RBD structures were overall very similar with a $C\alpha$ RMSD of 0.452 Å (Fig. 4A).

Nevertheless, significant structural rearrangements at the binding interface were
185 observed (Fig. 4A, 4B). Specifically, the small α -helix $\alpha_{364-370}$ (numbers mark start-end) moves towards the direction of RBM by a dramatic ~ 8.0 Å and transforms to a short β -sheet ($\beta_{367-370}$) which in turn forms a parallel β -sheet pair with $\beta_{102-104}$ in the CDR3 region. In addition, nudged by the CDR1, the short helix $\alpha_{383-388}$ swings towards the RBD core by ~ 4.0 Å.

190




Fig. 4. RBD is a very stable domain. (A, B) The overview (A) and expanded view (B) of the comparison between the ACE2-bound RBD (grey) and SR31-bound RBD (blue). SR31-binding deforms the RBD at the binding site (green) but not at the RBM region (yellow circle). The two SR31 CDRs involved in the deformation are shown as wheat cartoon. In B, two structure rearrangements (green) are shown at a different angle. The $\alpha_{383-388}$ helix in the ACE2-bound form is pushed towards the RBD core; and the short helix $\alpha_{364-370}$ is transformed into a β -strand ($\beta_{367-370}$) which forms a parallel β -sheet with $\beta_{102-104}$ from SR31 CDR3. (C) An indirect stability assay of the RBD using fluorescence-detection size exclusion chromatography. The RBD was incubated at 4 °C (black), 90 °C (red), and 99 °C (blue) for 20 min before loaded onto an analytical column
195
200

for gel filtration. The retention profile of RBD was monitored by intrinsic tryptophan fluorescence. (D) Three disulfide bonds (orange spheres) segregate the two motifs ($\alpha_{383-388}$ and $\beta_{367-370}$, green) from the RBM (orange cycle). The two SR31 CDRs are shown as wheat cartoon. $\alpha_{383-388}$ is tethered between Cys379/432 and Cys391/525; $\beta_{367-360}$ is tethered between Cys379/432 and Cys336/361.

210 Remarkable, the dramatic rearrangements did not cause noticeable conformational change of RBM (**Fig. 4A**) nor did it affect ACE2 binding (**Fig. 1C**). Given that RBD is a relatively small entity, and that the two surfaces are relatively close (~ 25 Å), this was somewhat unexpected. A probable explanation is that RBD is very rigid and hence stable. Indeed, as shown in **Fig. 4C**, RBD showed ultra-stability, with an apparent melting temperature of greater than 95 °C (20-min heating).

215 Intriguingly, the rearrangement happens at a region that is rich in disulfide bonds. Specifically, $\beta_{367-370}$ is tethered between the disulfide pairs Cys379-Cys432 and Cys336-Cys361, and $\alpha_{383-388}$ bridges Cys379-Cys432 and Cys391-Cys525 (**Fig. 4D**). Thus, the three disulfide bonds segregate the two local motifs from the rest of RBD, 220 preventing these conformational changes from propagating through the domain.

SR31 as a non-competing sybody for RBM binders

225 The neutral feature of SR31 so far suggests it could bind to RBD in addition to RBM binders such as MR17 and SR4 (35). Indeed, BLI assays showed no competition between SR31 and MR17 (**Fig. 5A**), indicating a ‘sandwich complex’ where the RBD is bound with both sybodies. This non-competing feature was also observed in the case of MR6 (**Fig. 5B**) which has also been shown to have neutralizing activities (35). As a further proof for the simultaneous binding, we determined the structure of the sandwich 230 complex SR31-RBD-MR17 (**Fig. 5C, Table 1**) to 2.10 Å resolution. The sandwich complex was similar to the individual MR17- and SR31-RBD complexes, with an overall C α RMSD of 0.667 and 0.375 Å, respectively. Aligning the sandwich complex with the MR17-RBD structure revealed no noticeable changes at the MR17-binding surface (**Fig. 5C**), reinforcing the idea that SR31-binding does not allosterically change 235 the RBM surface nor affect RBM binders.




Fig. 5. SR31 could pair with RBM nanobodies to bind RBD. (A, B) SR31 does not interfere with MR17 (A) or MR6 (B) for RBD-binding. In A, a RBD-coated sensor was pre-saturated in 200 nM of SR31 before incubating with SR31 alone (black) or a mixture (blue) of SR31 and MR17/MR6. In B, the sensor was saturated with MR6 before analyzed with SR31. For control purposes, the binding between RBD and the sybody used in the pre-incubation was also characterized (red). (C) Alignment of the sandwich complex structure containing MR17 (grey), RBD (red), and SR31 (light blue) to the two-component complex structure (RBD (green) and MR17, PDB ID 7c8w) (35).


245

SR31 fusion increases affinity and neutralization activity of MR17 and MR6

250 Although SR31 does not neutralize SARS-CoV-2 pseudovirus itself, its high-affinity may help increase the affinity of other neutralizing nanobodies through avidity effect by fusion. Indeed, the biparatopic fusion SR31-MR17 displayed remarkable increase in binding affinity compared to SR31 or MR17 alone. Its K_D of 0.3 nM (Fig. 255 6A) was lower than MR17 (K_D = 83.7 nM) (35) by 230 folds and lower than SR31 (K_D = 5.6 nM) by 17 folds. Consistently, SR31-MR17 neutralized SARS-CoV-2 pseudovirus 13 times more effectively (in molarity) than MR17 alone (Fig. 6B).

260 That SR31 can enhance potency of its fusion partner was also demonstrated in the case for MR6. At its free form, MR6 bound to RBD with a K_D of 23.2 nM (Fig. 6C), and showed modest neutralizing activity with an IC_{50} of $1.32 \mu\text{g mL}^{-1}$ (77.5 nM). Fusing

260 it to SR31 increased its affinity by over 40 folds, displaying a K_D of 0.5 nM (**Fig. 6D**).
 In line with this, SR31-MR6 showed a 27-fold higher neutralization activity compared
 to MR6, with an IC_{50} of 2.7 nM (0.08 μ g mL⁻¹) (**Fig. 6E**). Interestingly, when fused to
 265 MR3, a neutralizing antibody that had higher affinity (K_D = 1.0 nM) than SR31, the
 neutralizing activity decreased by 2 folds (**Fig. 6F**). Possible reasons include steric
 incompatibility caused by improper link length, and allosteric effects. Such hypothesis
 warrants future structural investigation.



270 **Fig. 6. SR31 increases binding affinity and neutralization activity of two fusion
 partners.** (A) BLI binding assay with immobilized RBD and the biparatopic sybody
 SR31-MR17 as analyte at increasing concentrations (nM). (B) Neutralization assay of
 275 MR17 (black) and SR31-MR17 (blue). (C, D) Binding kinetics for the RBD-binding
 by MR6 (C) or by SR31-MR6 (D). Concentrations (nM) of the sybodies used in the
 binding assay are labeled. (E) Neutralization assay of MR6 (black) and SR31-MR6
 (blue) using SARS-CoV-2 pseudovirus. (F) Summary of the comparison between

monovalent sybodies and divalent (biparatopic) sybodies for binding kinetics and neutralization activities.

Binding affinity and neutralizing activity are important characteristics of therapeutic antibodies. For modestly neutralizing nanobodies, the potency can be increased in a number of ways, including random mutagenesis (22), structure-based design (35), and fusion (35, 36, 42). Compared with the other two approaches, the fusion technique is more rapid, less involving and does not rely on prior structural information.

Depending on whether the two fusion partners are the same, divalent nanobodies can be categorized into two types: monoparatopic and biparatopic. Biparatopic fusions recognize two distinct epitopes on the same target. Therefore, they are more likely to be resistant to escape mutants because simultaneous mutations at two epitopes should occur at a much lower rate than at a single epitope.

Because of the minute size, SR31 could be used as an ‘add-on’ to monoclonal antibodies, scFv fragments, and other nanobodies to enhance their affinity and potency, especially for those with modest neutralizing activities. In addition, due to its small size and high stability, SR31 may be chemically modified as a vector to deliver small-molecule inhibitors specifically targeting SARS-CoV-2.

In summary, we have structurally characterized SR31, a high-affinity nanobody against SARS-CoV-2 RBD. Although lacking neutralizing activity alone, SR31 is an attractive biparatopic partner for RBM-binders owing to its distinct epitope from RBM. Our work presents a generally useful strategy and offers a simple and fast approach to enhance potency of modestly active antibodies against SARS-CoV2.

ACKNOWLEDGMENTS

305 We thank the staff members of the Large-scale Protein Preparation System for equipment maintenance and management, at the SSRF-BL18U1 and BL19U1 beamlines at National Facility for Protein Science (Shanghai) for technical support and assistance. This work has been supported by the Strategic Priority Research Program of CAS (XDB37020204, D.Li), Key Program of CAS Frontier Science (QYZDB-SSW-310 SMC037, D.Li), CAS Facility-based Open Research Program, the National Natural Science Foundation of China (31870726, D.Li), the National Key R&D Program of China (2020YFC0845900, D.La.), CAS president's international fellowship initiative (2020VBA0023, D.La.) and Shanghai Municipal Science and Technology Major Project (20431900402, D.La.).

315

AUTHOR CONTRIBUTIONS

320 H.Y., H.C. & T.L. characterized and crystalized the sybody-RBD complexes. B.Z. performed neutralization assays under supervision of D.La.. D.Li & W.Q. collected X-ray diffraction data. D.Li determined and analyzed structures. D.Li wrote the manuscript with inputs from H.Y., H.C., & T.L.

CONFLICT OF INTEREST

325 The authors claim no conflict of interest.

MATERIALS AND METHODS

Protein purification

330 SARS-CoV-2 RBD was expressed essentially as described (35). Briefly, a DNA fragment encoding, from N- to C-terminus, residues 330-541 of SARS-CoV2 S, a Gly-Thr linker, the 3C protease site (LEVLFQGP), a Gly-Ser linker, the Avi tag (GLNDIFEAQKIEWHE), a Ser-Gly linker, and a deca-His tag were cloned into the pFastBac-based vector. Baculovirus was generated in *Sf9* cells following the Invitrogen
335 Bac-to-Bac transfection protocol. High Five insect cells were infected with P3 virus. Medium was collected 48-60 h post infection and incubated with 3.0 mL of Ni-Sepharose Excel (Cat 17-3712-03, GE Healthcare) pre-equilibrated with **Buffer A** (150 mM NaCl, 20 mM Tris pH8.0). After batch binding for 2-3 h, the resin was washed with 20 mM of imidazole in **Buffer A** and eluted with 300 mM imidazole in **Buffer A**.

340 C-terminally His-tagged sybodies were expressed in *Escherichia coli* MC1061 cells. Cells carrying sybody-encoding genes in the vector pSb-init (41, 43) were grown in Terrific Broth (TB, 0.17 M KH₂PO₄ and 0.72 M K₂HPO₄, 1.2 % (w/v) tryptone, 2.4 % (w/v) yeast extract, 0.5% (v/v) glycerol) plus 25 mg L⁻¹ chloramphenicol to OD₆₀₀ of 0.5 at 37 °C. Cells were allowed to grow for another 1.5 h at 22 °C before induced with 0.02 % (w/v) arabinose for 17 h. Cells were harvested and lysed by osmotic shock as follows. Cell suspension in 20 mL of TES-high Buffer (0.5 M sucrose, 0.5 mM EDTA, and 0.2 M Tris-HCl pH 8.0) was first incubated at 4 °C for 30 min for dehydration. To the cell suspension, 40 mL of ice-cold MilliQ H₂O was added for rehydration at 4 °C for 1 h. The suspension was centrifuged at 20,000×g at 4 °C for 30 min to collect supernatant which contained periplasmic extracts. Appropriate buffers were added to the supernatant to have a final concentration of 150 mM NaCl, 2 mM MgCl₂, and 20 mM imidazole. The supernatant was then incubated with Ni-NTA resin pre-equilibrated with 20 mM of imidazole in **Buffer B** (150 mM NaCl and 20 mM Tris HCl pH 8.0).
345 After batch-binding for 2 h, the Ni-NTA resin were subsequently washed and eluted with 30 mM and 300 mM imidazole in **Buffer B**, before desalting into PBS buffer.
350

360 Divalent sybodies were engineered to have SR31 at the N-terminal and other sybodies at the C-terminal. The DNA fragments were linked together with sequences encoding Gly-Ser linkers at specified length by Gibson Assembly and insertion PCR. Divalent sybodies were expressed and purified essentially as for the monovalent sybodies.

For crystallization, SR31 or SR31-MR17 was mixed with RBD at a 1:1.5 molar

365 ratio. The mixture was then loaded onto a Superdex 200 column for gel filtration.
Fractions containing the complex were pooled and concentrated to 10 mg mL⁻¹.

Fluorescence-detection size-exclusion chromatography (FSEC)

370 To screen RBD binders by size exclusion chromatography (SEC) using unpurified sybodies, RBD was fluorescently labelled as follows. First the avi-tagged RBD was enzymatically biotinylated. It was then incubated with fluorescein-labeled streptavidin. The bright fluorescence of the RBD-streptavidin complex at visible wavelength enables convenient and specific monitoring of RBD SEC behavior without the need for purification.

375

380 To assess if sybody of interests binds RBD, purified or unpurified sybody was mixed with the fluorescent RBD before injecting on an analytical SEC column connected to a HPLC machine equipped with a fluorescence detector. The retention profile was then recorded by the fluorescence signal at the excitation/emission pair of 482/508 nm.

Bio-layer interferometry assay

385 Bio-layer interferometry (BLI) was used to measure binding kinetics between sybodies and RBD. Biotinylated RBD (2 µg mL⁻¹ in 0.005 %(v/v) Tween 20, 150 mM NaCl, 20 mM Tris HCl pH 8.0) was first bound to the SA sensor (Cat 18-5019, ForteBio) which was coated with streptavidin. The sensor was equilibrated (baseline) for 120 s at 30 °C. The sensor was then soaked with sybodies at various concentrations (association) for 200-300 s, before moving into sybody-free buffer for dissociation. BLI signal was monitored during the whole process. Data were fitted with a 1:1 stoichiometry using 390 the build-in software Analysis 10.0 for kinetic parameters. For competitive assay of the RBD between SR31 and ACE2, the RBD-coated sensor was saturated in 200 nM of SR31, before soaked in 25 nM SR31 with or without 25 nM of ACE2. As a control, BLI assays were also carried out by soaking the RBD-coated sensor in ACE2 without SR31. For competitive RBD-binding assays for different sybodies, the assays were 395 carried out the same manner as described above.

Pseudotyped particle production and neutralizing assay

396 To generate retroviral pseudotyped particles, HEK293T cells were co-transfected

400 with the vectors expressing the various viral envelope glycoproteins, the murine
leukemia virus core/packaging components (MLV Gag-Pol), and a retroviral transfect
vector expressing the green fluorescence protein (GFP). The S protein of SARS-CoV
and SARS-CoV2 in the vector phCMV were truncated by 19 amino acids at the C-
terminus. Pseudotyped particles generated this way were harvested 48 h post-
transfection by centrifugation and the supernatant was filtered through a 0.45- μ m
405 membrane before applying for neutralization assays.

410 Fifty microliters of VeroE6-hACE2 cells (10^4 cells/well) were seeded in a 48-well
plate. After 24 h, cells were infected with 100 μ L of pseudovirus prepared above. When
sybodies were included, they were incubated with the pseudovirus for 1 h at 37 °C
before infection. The supernatant of cell culture was removed 6 h after infection and
replaced with medium. Cells were allowed to grow for 72 h at 37 °C. GFP expression
level, as an indication of infectivity, was monitored by fluorescence-activated flow
cytometry analysis.

415 After 6 h of co-incubation, the supernatants were removed and the cells were
incubated in medium (Dulbecco's modified Eagle's medium-2% fetal calf serum) for
72 h at 37 °C. GFP expression was determined by fluorescence-activated flow
cytometry analysis. Cells incubated with medium-only were used as a control to
calculate percent inhibition.

420

Crystallization

425 Crystallization experiments were conducted using a Gryphon LCP robot. A two-
well sitting-drop plate was filled by 70 μ L of precipitant solution as the reservoir. To
each well, 100 nL of protein solution was touch-dispensed using the LCP dispenser of
the robot. The protein solution was then mixed with 100 nL of precipitant solution
delivered by the 96-headed tips. Plates were sealed with transparent tape (Cat HR4-506,
Hampton research) and incubated in a Rocker Imager 1000 at 20 °C for automated
imaging.

430 Crystals for the SR31-RBD complex were grown in 2.0 M Sodium formate, 0.1 M
Sodium acetate trihydrate pH 4.6. Cryo protection was achieved by adding 20 %(v/v)
glycerol to the mother liquor condition. Crystals for the SR31-MR17-RBD complex
were grown in 0.1 M cadmium chloride, 0.1 M Na-acetate pH 4.5, 30 % PEG 400, 4%
v/v (\pm)-1,3-butanediol. Cryo protection was achieved by adding 20 %(v/v) glycerol in
435 the mother liquor condition.

Desired crystals were cryo-protected, harvested using a MiTeGen loop under a microscope, and flash-cooled in liquid nitrogen before diffraction.

Data collection and structure determination

X-ray diffraction data were collected at beamline BL19U1 (44) at Shanghai Synchrotron Radiation Facility with a 50 x 50 μm beam on a Pilatus 6M detector, with oscillation of 0.5° and a wavelength of 0.97853 Å. Data were integrated using the software XDS (45), and scaled and merged using Aimless (46). The SR31-RBD structure was solved by molecular replacement using Phaser (47) with PDB IDs 6M0J and 5M13 (41) as the search model. The SR31-MR17-RBD structure was solved using the SR31-RBD and MR17 structure (35) as search models. The models were manually adjusted as guided by the $2F_o - F_c$ maps in Coot (48), and refined using Phenix (49). Structures were visualized using PyMol (50).

Data availability

The structure factors and coordinates were deposited in the protein data bank (PDB) under accession codes 7D2Z (SR31+RBD) and 7D30 (SR31-MR17+RBD).

Table 1. Data collection and refinement statistics.

	SR31 + RBD	SR31-MR17 + RBD
Data collection		
Space group	P 3 ₁ 2 1	P 6 ₅ 2 2
Cell dimensions		
<i>a, b, c</i> (Å)	92.39, 92.39, 101.15	73.38, 73.38, 478.36
α, β, γ (°)	90, 90, 120	90, 90, 120
Wavelength (Å)	0.97854	0.98754
Resolution (Å)	19.61 – 1.97 (2.04 – 1.97) ^a	49.70- 2.10 (2.16-2.10)
<i>R</i> _{merge}	0.091 (1.425)	0.140 (1.409)
<i>R</i> _{pim}	0.209 (0.336)	0.034 (0.373)
<i>I</i> / σ <i>I</i>	19.5 (1.7)	12.6 (2.0)
Completeness (%)	99.9 (100.0)	99.7 (96.6)
Multiplicity	19.8 (18.8)	18.6 (14.5)
<i>CC</i> * ^b	1.000 (0.949)	0.999 (0.965)
Refinement		
Resolution (Å)	19.61 – 1.97	49.70 - 2.10
No. reflections	35,702	46,078
<i>R</i> _{work} / <i>R</i> _{free}	0.1822 / 0.2071	0.1949 / 0.2359
No. atoms	2,916	3,892
Protein	2,592	3,437
Ligands	158	235
Solvent	166	220
No. residues	329	435
B-factors (Å ²)	49.49	50.52
Protein	48.01	48.17
Ligand/ion	73.11	78.91
Solvent	50.19	56.78
R.m.s deviations		
Bond lengths (Å)	0.008	0.008
Bond angles (°)	0.870	0.830
Ramachandran		
Favoured (%)	96.62	97.18
Allowed (%)	3.38	2.82
Outlier (%)	0	0
PDB ID	7D2Z	7D30

^aHighest resolution shell is shown in parenthesis. ^b $CC^* = \sqrt{\frac{2CC_{1/2}}{1+CC_{1/2}}}$

455 **REFERCNES**

1. C. Wang, P. W. Horby, F. G. Hayden, G. F. Gao, A novel coronavirus outbreak of global health concern. *Lancet* **395**, 470-473 (2020).
- 460 2. D. Wrapp *et al.*, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* **367**, 1260-1263 (2020).
3. A. C. Walls *et al.*, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* **181**, 281-292.e286 (2020).
4. J. Shang *et al.*, Cell entry mechanisms of SARS-CoV-2. *Proc Natl Acad Sci USA* **117**, 11727-11734 (2020).
- 465 5. M. Hoffmann *et al.*, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280.e278 (2020).
6. J. Lan *et al.*, Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature* **581**, 215-220 (2020).
- 470 7. J. Shang *et al.*, Structural basis of receptor recognition by SARS-CoV-2. *Nature* **581**, 221-224 (2020).
8. Q. Wang *et al.*, Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. *Cell* **181**, 894-904.e899 (2020).
9. R. Yan *et al.*, Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science* **367**, 1444-1448 (2020).
- 475 10. C. Xu *et al.*, Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM. *bioRxiv*, 2020.2006.2030.177097 (2020).
11. D. Zhou *et al.*, Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. *Nature Structural & Molecular Biology*, (2020).
- 480 12. M. Yuan *et al.*, A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. *Science* **368**, 630-633 (2020).
13. Y. Wu *et al.*, A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. *Science*, eabc2241 (2020).
14. R. Shi *et al.*, A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. *Nature* **584**, 120-124 (2020).
- 485 15. T. F. Rogers *et al.*, Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. *Science* **369**, 956-963 (2020).
16. D. F. Robbiani *et al.*, Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature* **584**, 437-442 (2020).
- 490 17. L. Premkumar *et al.*, The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Science Immunology* **5**, eabc8413 (2020).
18. D. Pinto *et al.*, Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature* **583**, 290-295 (2020).
- 495 19. L. Liu *et al.*, Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. *Nature* **584**, 450-456 (2020).
20. B. Ju *et al.*, Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature*, (2020).
21. J. Huo *et al.*, Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. *Cell host &*

500 22. *microbe*, S1931-3128(1920)30351-30356 (2020).

23. J. Huo *et al.*, Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. *Nature Structural & Molecular Biology*, (2020).

24. J. Hansen *et al.*, Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. *Science*, eabd0827 (2020).

505 25. Y. Cao *et al.*, Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. *Cell*, (2020).

26. X. Chi *et al.*, A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. *bioRxiv*, 2020.2005.2008.083964 (2020).

510 27. P. J. M. Brouwer *et al.*, Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. *Science*, eabc5902 (2020).

28. C. O. Barnes *et al.*, Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. *Cell* **182**, 828-842.e816 (2020).

515 29. N. K. Hurlburt *et al.*, Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. *bioRxiv : the preprint server for biology*, 2020.2006.2012.148692 (2020).

30. I. Jovčevska, S. Muyldermans, The Therapeutic Potential of Nanobodies. *BioDrugs* **34**, 11-26 (2020).

520 31. A. Larios Mora *et al.*, Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs. *mAbs* **10**, 778-795 (2018).

32. G. Van Heeke *et al.*, Nanobodies® as inhaled biotherapeutics for lung diseases. *Pharmacol Ther* **169**, 47-56 (2017).

33. M. Scully *et al.*, Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. *New England Journal of Medicine* **380**, 335-346 (2019).

525 34. L. Senolt, Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies. *F1000Res* **8**, F1000 Faculty Rev-1549 (2019).

35. D. Wrapp *et al.*, Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. *Cell* **181**, 1004-1015.e1015 (2020).

530 36. T. Li *et al.*, Potent synthetic nanobodies against SARS-CoV-2 and molecular basis for neutralization. *bioRxiv*, 2020.2006.2009.143438 (2020).

37. M. Schoof *et al.*, An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation. *bioRxiv*, 2020.2008.2008.238469 (2020).

535 38. L. Hanke *et al.*, An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. *Nat Commun* **11**, 4420 (2020).

39. J. D. Walter *et al.*, Synthetic nanobodies targeting the SARS-CoV-2 receptor-binding domain. *bioRxiv*, 2020.2004.2016.045419 (2020).

540 40. T. F. Custódio *et al.*, Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. *bioRxiv*, 2020.2006.2023.165415 (2020).

41. Y. Wu *et al.*, Identification of Human Single-Domain Antibodies against SARS-CoV-2. *Cell Host & Microbe* **27**, 891-898.e895 (2020).

42. I. Zimmermann *et al.*, Synthetic single domain antibodies for the conformational trapping of membrane proteins. *eLife* **7**, e34317 (2018).

43. Z. Zhang, Y. Wang, Y. Ding, M. Hattori, Structure-based engineering of anti-GFP nanobody tandems as ultra-high-affinity reagents for purification. *Scientific Reports* **10**, 6239 (2020).

43. I. Zimmermann *et al.*, Generation of synthetic nanobodies against delicate proteins. *Nat Protoc* **15**, 1707-1741 (2020).

545 44. W.-Z. Zhang *et al.*, The protein complex crystallography beamline (BL19U1) at the Shanghai Synchrotron Radiation Facility. *Nucl Sci Tech* **30**, 170 (2019).

45. W. Kabsch, XDS. *Acta crystallographica. Section D, Biological crystallography* **66**, 125-132 (2010).

550 46. P. R. Evans, G. N. Murshudov, How good are my data and what is the resolution? *Acta Crystallogr D* **69**, 1204-1214 (2013).

47. A. J. McCoy *et al.*, Phaser crystallographic software. *J Appl Crystallogr* **40**, 658-674 (2007).

48. P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot. *Acta Crystallogr D* **66**, 486-501 (2010).

555 49. P. D. Adams *et al.*, PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D* **66**, 213-221 (2010).

50. PyMOL. (Schrödinger, 2015), vol. 2015.

560 **Table S1. Sequences of biparatopic sybodies.**

Sybbody	Sequence ^a
SR31-MR17	QVQLVESGGGLVQAGGSLRLSCAASGFPVEVWRMEWYRQAPGKE REGVAAIESYGHGTRYADSVKGRFTISRDNAKNTVYLQMNSLKPED TAVYYCNVKDDGQLAYHYDYWGQGTQTVSGGGGSGGGGGSGGG GSGGGGSGGGSGGGSGSSSQVQLVESGGGLVQAGGSLRLSCAAS GFPVWQGEMAWYRQAPGKEREWVAIISSMGYKTYYADSVKGRFTI SRDNAKNTVYLQMNSLKPEDTAVYYCAVMVGFYAGQGTQTVS
SR31-MR6	QVQLVESGGGLVQAGGSLRLSCAASGFPVEDTWMWYRQAPGKE REWVAIITSWGFKTYYADSVKGRFTISRDNAKNTVYLQMNSLKP DTAVYYCNVKDEGDTASAYDYWGQGTQTVSGGGGSGGGSGGG GSGSSSQVQLVESGGGLVQAGGSLRLSCAASGFPVWQGEMAWYRQ APGKEREWVAIISSMGYKTYYADSVKGRFTISRDNAKNTVYLQM SLKPEDTAVYYCAVMVGFYAGQGTQTVS
SR31-MR3	QVQLVESGGGLVQAGGSLRLSCAASGFPVNAHFMYWYRQAPGKER EWVAAIISYGRILYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTA VYYCNVKDYGAASWEYDYWGQGTQTVSGGGGSGGGSGGG GGGGSGGGSGGGSGSSSQVQLVESGGGLVQAGGSLRLSCAASGF PVWQGEMAWYRQAPGKEREWVAIISSMGYKTYYADSVKGRFTISR DNAKNTVYLQMNSLKPEDTAVYYCAVMVGFYAGQGTQTVS

^aThe sequences include ‘GSSS’ at the N-terminal, and ‘AGRAGEQKLISEEDLNSAVDHHHHHH’ at the C-terminal which contains a myc-tag (italic) for ELISA and a hexahistidine tag for purification.